Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Review on Mucormycosis: Pathogenesis, Epidemiology, Microbiology and Diagnosis

Author(s): Aditya Sharma, Md Aftab Alam*, Shivang Dhoundiyal and Pramod Kumar Sharma

Volume 24, Issue 1, 2024

Published on: 08 September, 2023

Article ID: e220823220209 Pages: 10

DOI: 10.2174/1871526523666230822154407

Price: $65

Abstract

Mucormycosis is a serious and invasive fungal infection caused by Mucorales fungi. This review article provides a concise overview of the pathogenesis, epidemiology, microbiology, and diagnosis of mucormycosis. The introduction section highlights the key microbiological properties of the pathogen and delves into the underlying mechanisms of mucormycosis pathogenesis, including the invasion and proliferation of the fungus within the host. The description of the disease section focuses on the epidemiology of mucormycosis, including its incidence, risk factors, and geographical distribution. It also explores the specific context of mucormycosis infection about COVID-19 and diabetes mellitus, highlighting the increased susceptibility observed in individuals with these conditions. A case study illustrates the clinical manifestations and challenges associated with mucormycosis, emphasizing the importance of early detection. Additionally, the review discusses the diagnosis of mucormycosis, emphasizing the significance of clinical assessment, radiological imaging, and microbiological tests for accurate and timely detection of the infection.

Regarding treatment, the article covers the various therapeutic approaches, including antifungal therapy, surgical interventions, and management of underlying predisposing conditions. The limitations and challenges associated with treatment options are also addressed. This review aims to provide a comprehensive understanding of mucormycosis, equipping healthcare professionals with valuable insights into its pathogenesis, epidemiology, microbiology, and diagnostic strategies. By enhancing knowledge and awareness of this fungal infection, this review can improve patient outcomes through early diagnosis and appropriate management.

Graphical Abstract

[1]
Dam P, Cardoso MH, Mandal S, et al. Surge of mucormycosis during the COVID-19 pandemic. Travel Med Infect Dis 2023; 52: 102557.
[http://dx.doi.org/10.1016/j.tmaid.2023.102557] [PMID: 36805033]
[2]
Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: A systematic review and meta-analysis. J Infect 2020; 81(2): 266-75.
[http://dx.doi.org/10.1016/j.jinf.2020.05.046] [PMID: 32473235]
[3]
Stone N, Gupta N, Schwartz I. Mucormycosis: Time to address this deadly fungal infection. Lancet Microbe 2021; 2(8): e343-4.
[http://dx.doi.org/10.1016/S2666-5247(21)00148-8] [PMID: 35544192]
[4]
Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. Clin Microbiol Infect 2021; 27(1): 9-11.
[http://dx.doi.org/10.1016/j.cmi.2020.09.025] [PMID: 32979569]
[5]
Özbek L, Topçu U, Manay M, et al. COVID-19–associated mucormycosis: A systematic review and meta-analysis of 958 cases. Clin Microbiol Infect 2023; 29(6): 722-31.
[http://dx.doi.org/10.1016/j.cmi.2023.03.008] [PMID: 36921716]
[6]
Saadi MHG, Hosseini SA, Khodamoradi Z, Mokhtaryan M, Omidifar N, Moghadami M. Comparison of mucormycosis infection between patients with and without a history of COVID-19 infection: A retrospective cohort study. Trans R Soc Trop Med Hyg 2023; 117(3): 174-8.
[http://dx.doi.org/10.1093/trstmh/trac078] [PMID: 36001888]
[7]
COVID-19 weekly epidemiological update, 18 May 2021. Geneva: World Health Organization.. 2021.
[8]
Ahmadikia K, Hashemi SJ, Khodavaisy S, et al. The double‐edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza‐associated mucormycosis versus COVID‐19 associated mucormycosis. Mycoses 2021; 64(8): 798-808.
[http://dx.doi.org/10.1111/myc.13256] [PMID: 33590551]
[9]
Garg D, Muthu V, Sehgal IS, et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): Case report and systematic review of literature. Mycopathologia 2021; 186(2): 289-98.
[http://dx.doi.org/10.1007/s11046-021-00528-2] [PMID: 33544266]
[10]
Ranjbar K, Moghadami M, Mirahmadizadeh A, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: A triple-blinded randomized controlled trial. BMC Infect Dis 2021; 21(1): 337.
[http://dx.doi.org/10.1186/s12879-021-06045-3] [PMID: 33838657]
[11]
Morales-Franco B, Nava-Villalba M, Medina-Guerrero EO, et al. Hostpathogen molecular factors contribute to the pathogenesis of Rhizopus spp. In diabetes mellitus. Curr Trop Med Rep 2021; 8(1): 6-17.
[http://dx.doi.org/10.1007/s40475-020-00222-1] [PMID: 33500877]
[12]
Katragkou A, Walsh TJ, Roilides E. Why is mucormycosis more difficult to cure than more common mycoses? Clin Microbiol Infect 2014; 20 (Suppl. 6): 74-81.
[http://dx.doi.org/10.1111/1469-0691.12466] [PMID: 24279587]
[13]
Grant P, Skilbeck CJ. Rhinocerebral mucormycosis: A devastating rhinological condition. Pract Diabetes 2014; 31(1): 37-9.
[http://dx.doi.org/10.1002/pdi.1826]
[14]
Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin Microbiol Infect 2009; 15 (Suppl. 5): 2-9.
[http://dx.doi.org/10.1111/j.1469-0691.2009.02972.x] [PMID: 19754749]
[15]
Szebenyi C, Gu Y, Gebremariam T, et al. CotH genes are necessary for normal spore formation and virulence in mucor lusitanicus. MBio 2023; 14(1): e03386-22.
[http://dx.doi.org/10.1128/mbio.03386-22] [PMID: 36625576]
[16]
Sullivan DJ, Moran GP, Coleman DC. Fungal Infections of Humans Fungi: Biology and Applications. Wiley 2011; pp. 257-78.
[http://dx.doi.org/10.1002/9781119976950.ch10]
[17]
Walther G, Wagner L, Kurzai O. Updates on the taxonomy of mucorales with an emphasis on clinically important taxa. J Fungi 2019; 5(4): 106.
[http://dx.doi.org/10.3390/jof5040106] [PMID: 31739583]
[18]
Krüger W, Vielreicher S, Kapitan M, Jacobsen I, Niemiec M. Fungal-bacterial interactions in health and disease. Pathogens 2019; 8(2): 70.
[http://dx.doi.org/10.3390/pathogens8020070] [PMID: 31117285]
[19]
Köhler JR, Casadevall A, Perfect J. The spectrum of fungi that infects humans. Cold Spring Harb Perspect Med 2015; 5(1): a019273.
[http://dx.doi.org/10.1101/cshperspect.a019273] [PMID: 25367975]
[20]
Spellberg B. Vaccines for invasive fungal infections. F1000 Med Rep 2011; 3: 13.
[http://dx.doi.org/10.3410/M3-13] [PMID: 21876719]
[21]
Shoham S, Levitz SM. The immune response to fungal infections. Br J Haematol 2005; 129(5): 569-82.
[http://dx.doi.org/10.1111/j.1365-2141.2005.05397.x] [PMID: 15916679]
[22]
Soliman SSM, Baldin C, Gu Y, et al. Mucoricin is a ricin-like toxin that is critical for the pathogenesis of mucormycosis. Nat Microbiol 2021; 6(3): 313-26.
[http://dx.doi.org/10.1038/s41564-020-00837-0] [PMID: 33462434]
[23]
Olsson S, Bonfante P, Pawlowska TE. Ecology and evolution of fungal-bacterial interactions InThe Fungal Community Its Organization and Role in the Ecosystem. (4th ed.). CRC Press Taylor & Francis Group 2017; pp. 563-84.
[24]
Reid G, Lynch JP III, Fishbein MC, Clark NM. Mucormycosis. Semin Respir Crit Care Med 2020; 41(1): 099-114.
[http://dx.doi.org/10.1055/s-0039-3401992] [PMID: 32000287]
[25]
Song Y, Qiao J, Giovanni G, et al. Mucormycosis in renal transplant recipients: Review of 174 reported cases. BMC Infect Dis 2017; 17(1): 283.
[http://dx.doi.org/10.1186/s12879-017-2381-1] [PMID: 28420334]
[26]
Chikley A, Ben-Ami R, Kontoyiannis DP. Mucormycosis of the central nervous system. J Fungi 2019; 5(3): 59.
[http://dx.doi.org/10.3390/jof5030059] [PMID: 31288475]
[27]
Kashyap S, Bernstein J, Ghanchi H, Bowen I, Cortez V. Diagnosis of rhinocerebral mucormycosis by treatment of cavernous right internal carotid artery occlusion with mechanical thrombectomy: special case presentation and literature review. Front Neurol 2019; 10: 264.
[http://dx.doi.org/10.3389/fneur.2019.00264] [PMID: 30972005]
[28]
Kawahara Y, Wada S, Nijima H, et al. Rhinocerebral mucormycosis with temporal artery thrombosis in an adolescent following hla-haploidentical stem cell transplantation. J Pediatr Hematol Oncol 2018; 40(7): e461-3.
[http://dx.doi.org/10.1097/MPH.0000000000001020] [PMID: 29200154]
[29]
Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: A systematic review and meta-analysis. SSRN Electron J 2020.
[http://dx.doi.org/10.2139/ssrn.3594598]
[30]
Loh JT, Lam KP. Fungal infections: Immune defense, immunotherapies and vaccines. Adv Drug Deliv Rev 2023; 196: 114775.
[http://dx.doi.org/10.1016/j.addr.2023.114775] [PMID: 36924530]
[31]
Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: A clinical and diagnostic perspective from China. Mycopathologia 2020; 185(4): 599-606.
[http://dx.doi.org/10.1007/s11046-020-00462-9] [PMID: 32737747]
[32]
Suganya R, Malathi N, Karthikeyan V, Janagaraj VD. Mucormycosis: A brief review. J Pure Appl Microbiol 2019; 13(1): 161-5.
[http://dx.doi.org/10.22207/JPAM.13.1.16]
[33]
Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin Microbiol Infect 2019; 25(1): 26-34.
[http://dx.doi.org/10.1016/j.cmi.2018.07.011] [PMID: 30036666]
[34]
Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the european confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis 2019; 19(12): e405-21.
[http://dx.doi.org/10.1016/S1473-3099(19)30312-3] [PMID: 31699664]
[35]
Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases. Med Mycol 2018; 56(1): 29-43.
[http://dx.doi.org/10.1093/mmy/myx017] [PMID: 28431008]
[36]
Mekonnen ZK, Ashraf DC, Jankowski T, et al. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthal Plast Reconstr Surg 2021; 37(2): e40-80.
[http://dx.doi.org/10.1097/IOP.0000000000001889] [PMID: 33229953]
[37]
Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID 19. Cureus 2020; 12(9): e10726.
[http://dx.doi.org/10.7759/cureus.10726] [PMID: 33145132]
[38]
Banerjee A, Das M, Verma P, et al. COVID-19 and mucormycosis of orofacial region: A scoping review. Cureus 2023; 15(4): e37984.
[http://dx.doi.org/10.7759/cureus.37984] [PMID: 37223184]
[39]
Tahiri G, Lax C, Cánovas-Márquez JT, et al. Mucorales and mucormycosis: Recent insights and future prospects. J Fungi 2023; 9(3): 335.
[http://dx.doi.org/10.3390/jof9030335] [PMID: 36983503]
[40]
Lamoth F. Novel approaches in the management of mucormycosis. Curr Fungal Infect Rep 2023; 17(2): 98-107.
[http://dx.doi.org/10.1007/s12281-023-00463-3] [PMID: 37360854]
[41]
Harpf V, Rambach G, Parth N, et al. Complement, but not platelets, plays a pivotal role in the outcome of mucormycosis In vivo. J Fungi 2023; 9(2): 162.
[http://dx.doi.org/10.3390/jof9020162] [PMID: 36836277]
[42]
Drogari-Apiranthitou M, Skiada A, Panayiotides I, et al. Epidemiology of mucormycosis in greece; results from a nationwide prospective survey and published case reports. J Fungi 2023; 9(4): 425.
[http://dx.doi.org/10.3390/jof9040425] [PMID: 37108880]
[43]
Azhar A, Khan WH, Khan PA, Alhosaini K, Owais M, Ahmad A. Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach. J Infect Public Health 2022; 15(4): 466-79.
[http://dx.doi.org/10.1016/j.jiph.2022.02.007] [PMID: 35216920]
[44]
Skiada A, Drogari-Apiranthitou M, Pavleas I, Daikou E, Petrikkos G. Global cutaneous mucormycosis: A systematic review. J Fungi 2022; 8(2): 194.
[http://dx.doi.org/10.3390/jof8020194] [PMID: 35205948]
[45]
Dannaoui E. Recent developments in the diagnosis of mucormycosis. J Fungi 2022; 8(5): 457.
[http://dx.doi.org/10.3390/jof8050457] [PMID: 35628713]
[46]
Smith C, Lee SC. Current treatments against mucormycosis and future directions. PLoS Pathog 2022; 18(10): e1010858.
[http://dx.doi.org/10.1371/journal.ppat.1010858] [PMID: 36227854]
[47]
Alloush TK, Mansour O, Alloush AT, et al. Rhino-orbito-cerebral mucormycosis during the COVID-19 third wave in 2021: An Egyptian preliminary report from a single tertiary hospital. Neurol Sci 2022; 43(2): 799-809.
[http://dx.doi.org/10.1007/s10072-021-05740-y] [PMID: 34787754]
[48]
Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. Eur J Ophthalmol 2022; 32(4): NP11-6.
[http://dx.doi.org/10.1177/11206721211009450] [PMID: 33843287]
[49]
Sharma A, Goel A. Mucormycosis: Risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic. Folia Microbiol 2022; 67(3): 363-87.
[http://dx.doi.org/10.1007/s12223-021-00934-5] [PMID: 35220559]
[50]
Niyazi D, Belcheva M, Vergiev S, Kaleva V, Stoeva T. A case of primary multifocal cutaneous mucormycosis in a pediatric patient with newly diagnosed acute lymphoblastic leukemia. Medicina 2023; 59(5): 905.
[http://dx.doi.org/10.3390/medicina59050905] [PMID: 37241137]
[51]
Keerthika R, Narwal A, Kamboj M, et al. Mucor infection associated with global COVID-19 pandemic - an institutional histopathological study. Med Oral Patol Oral Cir Bucal 2023; 28(2): e99-e107.
[http://dx.doi.org/10.4317/medoral.25130] [PMID: 36806020]
[52]
Hussain MK, Ahmed S, Khan A, Siddiqui AJ, Khatoon S, Jahan S. Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents. Eur J Med Chem 2023; 246: 115010.
[http://dx.doi.org/10.1016/j.ejmech.2022.115010] [PMID: 36566630]
[53]
Varaiya A, Sundaresan A. Emerging mucormycosis: Problems and treatments.In: Fungi and Fungal Products in Human Welfare and Biotechnology. Singapore: Springer Nature Singapore 2023; pp. 97-125.
[54]
Mahler B, Parliteanu OA, Alexe O, et al. Mucormycosis in a patient with Severe COVID-19 Disease—The First Case Report in Romania and a Literature Review. Med 2023; 59(3): 555.
[http://dx.doi.org/10.3390/medicina59030555] [PMID: 36984555]
[55]
Jacobsen ID. Mouse Models of Mucormycosis. Methods Mol Biol 2023; 2667: 181-96.
[http://dx.doi.org/10.1007/978-1-0716-3199-7_14]
[56]
Aasia Batool S, Kumari U, Surani S. Two rare diseases, one patient: A case report of mucormycosis and granulomatous polyangiitis. Case Rep Infect Dis 2023; 2023: 1-5.
[http://dx.doi.org/10.1155/2023/7934700] [PMID: 37207042]
[57]
Reid G, Lynch JP III, Fishbein MC, Clark NM. Mucormycosis. Semin Respir Crit Care Med 2020; 41(1): 99-114.
[http://dx.doi.org/10.1055/s-0039-3401992] [PMID: 32000287]
[58]
Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021; 15(4): 102146.
[http://dx.doi.org/10.1016/j.dsx.2021.05.019] [PMID: 34192610]
[59]
Prakash H, Chakrabarti A. Epidemiology of mucormycosis in India. Microorganisms 2021; 9(3): 523.
[http://dx.doi.org/10.3390/microorganisms9030523] [PMID: 33806386]
[60]
Patel A, Agarwal R, Rudramurthy SM, et al. Multicenter epidemiologic study of coronavirus disease–associated mucormycosis, India. Emerg Infect Dis 2021; 27(9): 2349-59.
[http://dx.doi.org/10.3201/eid2709.210934] [PMID: 34087089]
[61]
Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med 2021; 42: 264.e5-8.
[http://dx.doi.org/10.1016/j.ajem.2020.09.032] [PMID: 32972795]
[62]
Steinbrink JM, Miceli MH. Mucormycosis. Infect Dis Clin 2021; 35(2): 435-52.
[http://dx.doi.org/10.1016/j.idc.2021.03.009] [PMID: 34016285]
[63]
Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: A deadly addition to the pandemic spectrum. J Laryngol Otol 2021; 135(5): 442-7.
[http://dx.doi.org/10.1017/S0022215121000992] [PMID: 33827722]
[64]
Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V. Sino-orbital mucormycosis in a COVID-19 patient: A case report. Int J Surg Case Rep 2021; 82: 105957.
[http://dx.doi.org/10.1016/j.ijscr.2021.105957] [PMID: 33964720]
[65]
Agrawal GA, Ravani SA, Leuva P, Modi P, Amin K. Rise of the phoenix: Mucormycosis in COVID-19 times. Indian J Ophthalmol 2021; 69(6): 1563-8.
[http://dx.doi.org/10.4103/ijo.IJO_310_21] [PMID: 34011742]
[66]
Eker C, Tarkan O, Surmelioglu O, et al. Alternating pattern of rhino-orbital–cerebral mucormycosis with COVID-19 in diabetic patients. Eur Arch Otorhinolaryngol 2023; 280(1): 219-26.
[http://dx.doi.org/10.1007/s00405-022-07526-0] [PMID: 35768700]
[67]
Saldanha M, Reddy R, Vincent MJ. Title of the article: Paranasal mucormycosis in COVID-19 patient. Indian J Otolaryngol Head Neck Surg 2021; (Apr): 1-4.
[http://dx.doi.org/10.1007/s12070-021-02574-0] [PMID: 33903850]
[68]
Khatri A, Chang KM, Berlinrut I, Wallach F. Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient – Case report and review of literature. J Mycol Med 2021; 31(2): 101125.
[http://dx.doi.org/10.1016/j.mycmed.2021.101125] [PMID: 33857916]
[69]
Buil JB, van Zanten ARH, Bentvelsen RG, et al. Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021. Euro Surveill 2021; 26(23): 2100510.
[http://dx.doi.org/10.2807/1560-7917.ES.2021.26.23.2100510] [PMID: 34114540]
[70]
Rocha ICN, Hasan MM, Goyal S, et al. COVID‐19 and mucormycosis syndemic: Double health threat to a collapsing healthcare system in India. Trop Med Int Health 2021; 26(9): 1016-8.
[http://dx.doi.org/10.1111/tmi.13641] [PMID: 34117677]
[71]
Mishra N, Mutya VSS, Thomas A, et al. A case series of invasive mucormycosis in patients with COVID-19 infection. Int J Otorhinolaryngol Head Neck Surg 2021; 7(5): 867-70.
[http://dx.doi.org/10.18203/issn.2454-5929.ijohns20211583]
[72]
Arana C, Cuevas Ramírez RE, Xipell M, et al. Mucormycosis associated with COVID‐19 in two kidney transplant patients. Transpl Infect Dis 2021; 23(4): e13652.
[http://dx.doi.org/10.1111/tid.13652] [PMID: 34038014]
[73]
Nehara HR, Puri I, Singhal V, Ih S, Bishnoi BR, Sirohi P. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: Case series from the north-western part of India. Indian J Med Microbiol 2021; 39(3): 380-3.
[http://dx.doi.org/10.1016/j.ijmmb.2021.05.009] [PMID: 34052046]
[74]
Kumar M, Sarma DK, Shubham S, et al. Mucormycosis in COVID-19 pandemic: Risk factors and linkages. Curr Res Microb Sci 2021; 2: 100057.
[http://dx.doi.org/10.1016/j.crmicr.2021.100057] [PMID: 34396355]
[75]
Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi 2019; 5(1): 26.
[http://dx.doi.org/10.3390/jof5010026] [PMID: 30901907]
[76]
Samaddar A, Shrimali T, Sharma A. Mucormycosis caused by Apophysomyces species: An experience from a tertiary care hospital in Western India and systematic review of global cases. Mycoses 2023; 66(3): 181-95.
[http://dx.doi.org/10.1111/myc.13538] [PMID: 36227645]
[77]
Muthu V, Agarwal R, Rudramurthy SM, et al. Multicenter case–control study of COVID-19–Associated mucormycosis outbreak, India. Emerg Infect Dis 2023; 29(1): 8-19.
[http://dx.doi.org/10.3201/eid2901.220926] [PMID: 36573628]
[78]
Osman NA, Anwar MM, Singh B, Gupta GK, Rabie AM. A peek behind the curtain in the diagnosis and management of COVID-19-Associated Mucormycosis (CAM). J Egypt Public Health Assoc 2023; 98(1): 4.
[http://dx.doi.org/10.1186/s42506-022-00125-1] [PMID: 36859556]
[79]
Bonifaz A, Tirado-Sánchez A, Araiza J, Hernández-Medel ML. Mucormycosis in the COVID-19 scenario beyond hospitalized patients. Future Microbiol 2023; 18(1): 5-8.
[http://dx.doi.org/10.2217/fmb-2022-0147] [PMID: 36648217]
[80]
Gupta S, Goyal R, Kaore NM. Rhino-orbital-cerebral mucormycosis: Battle with the deadly enemy. Indian J Otolaryngol Head Neck Surg 2020; 72(1): 104-11.
[http://dx.doi.org/10.1007/s12070-019-01774-z] [PMID: 32158665]
[81]
Chauhan K, Soni D, Sarkar D, et al. Mucormycosis after COVID-19 in a patient with diabetes. Lancet 2021; 398(10301): e10.
[http://dx.doi.org/10.1016/S0140-6736(21)01641-X] [PMID: 34363754]
[82]
Li C, Gong Z, Pataer P, Shao B, Fang C. A retrospective analysis for the management of oromaxillofacial invasive mucormycosis and systematic literature review. BMC Oral Health 2023; 23(1): 115.
[http://dx.doi.org/10.1186/s12903-023-02823-4] [PMID: 36810012]
[83]
Joshi AR, Muthe MM, Patankar SH, Athawale A, Achhapalia Y CT. and MRI findings of invasive mucormycosis in the setting of covid-19: experience from a single center in India. AJR Am J Roentgenol 2021; 217(6): 1431-2.
[http://dx.doi.org/10.2214/AJR.21.26205] [PMID: 34161127]
[84]
SeyedAlinaghi S, Karimi A, Barzegary A, et al.. Retracted: Mucormycosis infection in patients with COVID ‐19: A systematic review. Health Sci Rep 2022; 5(2): e529.
[http://dx.doi.org/10.1002/hsr2.529] [PMID: 35252593]
[85]
Klimko N, Khostelidi S, Shadrivova O, et al. Contrasts between mucormycosis and aspergillosis in oncohematological patients. Med Mycol 2019; 57 (Suppl. 2): S138-44.
[http://dx.doi.org/10.1093/mmy/myy116] [PMID: 30816977]
[86]
Dulski TM, DeLong M, Garner K, et al. Notes from the Field: COVID-19–Associated Mucormycosis — Arkansas, July–September 2021. MMWR Morb Mortal Wkly Rep 2021; 70(50): 1750-1.
[http://dx.doi.org/10.15585/mmwr.mm7050a3] [PMID: 34914674]
[87]
Martínez-Herrera E, Julián-Castrejón A, Frías-De-León MG, Moreno-Coutiño G. Rhinocerebral mucormycosis to the rise? The impact of the worldwide diabetes epidemic. An Bras Dermatol 2021; 96(2): 196-9.
[http://dx.doi.org/10.1016/j.abd.2020.06.008] [PMID: 33531184]
[88]
Essar MY, Khan H, Babar MS, et al. Mucormycosis, conflicts and COVID‐19: A deadly recipe for the fragile health system of Afghanistan. Int J Health Plann Manage 2022; 37(1): 543-6.
[http://dx.doi.org/10.1002/hpm.3292] [PMID: 34333804]
[89]
G Alshahawey M,. S El-Housseiny G, S Elsayed N, Y Alshahrani M, Wakeel LMEL, M Aboshanab K. New insights on mucormycosis and its association with the COVID-19 pandemic. Future Sci OA 2022; 8(2): FSO772.
[http://dx.doi.org/10.2144/fsoa-2021-0122] [PMID: 35059222]
[90]
Alexander BD, Lamoth F, Heussel CP, et al. Guidance on imaging for invasive pulmonary aspergillosis and mucormycosis: From the imaging working group for the revision and update of the consensus definitions of fungal disease from the EORTC/MSGERC. Clin Infect Dis 2021; 72 (Suppl. 2): S79-88.
[http://dx.doi.org/10.1093/cid/ciaa1855] [PMID: 33709131]
[91]
Chakrabarti A, Singh S. Management of Mucormycosis. Curr Fungal Infect Rep 2020; 14(4): 348-60.
[http://dx.doi.org/10.1007/s12281-020-00406-2]
[92]
Pal P, Chatterjee N, Ghosh S, et al. COVID associated mucormycosis: A study on the spectrum of clinical, biochemical and radiological findings in a series of ten patients. J Assoc Physicians India 2021; 69(10): 11-2.
[PMID: 34781648]
[93]
Bigot J, Godmer A, Prudenté L, et al. Diagnosis of mucormycosis using an intercalating dye-based quantitative PCR. Med Mycol 2022; 60(4): myac015.
[http://dx.doi.org/10.1093/mmy/myac015] [PMID: 35188208]
[94]
Fuloria S, Fuloria N, Subramaniyan V, et al. COVID-19-associated mucormycosis and treatments. Asian Pac J Trop Med 2021; 14(9): 401.
[http://dx.doi.org/10.4103/1995-7645.326253]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy